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Objective: Cineole has mucolytic, bronchodilating and anti-inflammatory properties and reduces the exacerbation
rate in patients suffering from COPD, as well as ameliorates symptoms in patients suffering from asthma and
rhinosinusitis. Based on these effects, we therefore postulated the hypothesis that patients with acute bronchitis
would also benefit from therapy with Cineole.
Methods: As part of a double-blind, placebo-controlled, multi-center-study, a total of 242 patients with confirmed
acute bronchitis was randomly selected to participate. Over a period of 10 days, all patients were administered
3 x 200 mg of Cineole, or a respective placebo, per day. The primary outcome measure was a Bronchitis Sum Score,
which summarises the relevant symptoms of acute bronchitis.
Results: After 4 days of treatment it was notable, that the patient group treated with Cineole, showed significantly
more improvements of the bronchitis-sum-score than those of the placebo group (p = 0.0383). The statistical
significant difference of the individual outcome measures was especially underlined by the frequency of cough fits
by p = 0.0001 after 4 days.
Conclusions: The effects of Cineole in the treatment of acute bronchitis were clearly measurable and could be
proven after a treatment period of merely 4 days. This study corroborates the fact that Cineole actively and
significantly reduces cough frequency after four days. Therefore it has been shown to have a great socioeconomic
impact.
Trial registration: ISRCTN: ISRCTN37784439
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Acute Bronchitis is one of the most common reasons for
patient visits to ambulatory care or physicians. Frequently,
it develops during the course of a common cold with a
predominant symptom of dry or productive cough. On
average, more than 50% of practice visits for acute bron-
chitis result in the prescription of antibiotics, although this
is predominantly caused by viral infections. Evidence-
based reviews and meta-analyses of randomized, con-
trolled trials conclude that routine antibiotic treatment
does not provide major clinical benefits in adults with
acute bronchitis [1-7].* Correspondence: jfischerp@aol.de
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distribution, and reproduction in any mediumThe primary goal should be the reduction of the fre-
quency of cough fits, whereas treatment with antitus-
sives is not recommended and should be reserved for
specific exceptions. Mucolytic agents as aromatic essen-
tial oils, such as eucalyptus or peppermint oil, have a
long history in treatment of respiratory inflammations.
The main constituent of eucalyptus oil is Cineole, which
has been proven as being effective in the treatment of
respiratory diseases, such as rhinosinusitis, asthma and
COPD [8-10]. This is essentially due to its mucolytic
and primary anti-inflammatory effects. Therefore, the
clinical effectiveness of Cineole has been repeatedly
proven and established in the context of controlled cli-
nical studies. As Cineole accelerates the beat frequency
of the cilias in the mucous membrane, as well as actinged Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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agent, it has to be postulated that it will be effective in
treating symptoms of acute bronchitis. Therefore, in
order to investigate the therapeutic effects of Cineole in
the treatment of acute bronchitis, we conducted a ran-
domized, placebo-controlled, multi-center study.
Patients and methods
Study design
This randomised, double-blind, placebo-controlled, para-
llel-group study was conducted in the practices of 3
general practitioners, 2 specialists in pneumology, 1 in-
ternal medicine and 1 ENT practice. In accordance with
the Helsinki Declaration, the study was approved by the
appropriate authorities and ethics committees, respon-
sible for the 7 participating centers. Furthermore, all
patients provided an explicit, written consent form, prior
to their participation and the commencement of the
study.
Patients were randomly assigned to one of the two treat-
ment groups with stratification according to the clinical
centers. Patients were then given the necessary dose of
capsules, each containing either 200 mg Cineole, or no
active ingredient. The dosage for each group amounted to
1 capsule, taken 3 times daily, resulting in a total dose of
600 mg of Cineole per day. The placebo control group
received an equal dose of placebo capsules. In order to
avoid patients from recognising the smell of Cineole, all
patients were instructed to take the capsules with mineral
water, half an hour before meals. All capsules, containing
either the active substance, or the placebo, were organo-
leptically identical and sealed in blister stripes. All patients
visited the practices at the beginning of the study, as well
as in the subsequent 4 and 10 days.
Enrolment of participants
The diagnosis of acute bronchitis was confirmed accor-
ding to the criteria of Wenzel [7]. The study was limited
to adult patients, aged 18 – 70 years, with a diagnosis of
acute bronchitis not longer than 7 days. All eligible par-
ticipants had a Bronchitis-Sum-Score of 7 or higher. Pa-
tients were excluded if they had severe medical conditions
with relevant influence on the acute bronchitis.
Outcome measures
As primary endpoint a Bronchitis-Sum-Score summaris-
ing relevant symptoms of acute bronchitis was defined
as multiple criteria composed of the parameters dyspnea,
sputum, frequency of cough, thoracic pain, auscultation
and lung function – all equally weighted. These were
specified for the intensity of dyspnea in scores as 0 = no
difficulties in breathing, 1 =minor difficulties in brea-
thing, 2 =moderate difficulties in breathing, 3 = severe
difficulties in breathing and 4 = unbearable difficulties inbreathing. Quantity of secretion was assessed by scores
(0 = no secretion, 1 = < 2 ml (i.e. very modest), 2 = < 5 ml
(i.e. modest), 3 = < 10 ml (i.e. moderate), 4 = > 10 ml
(i.e. very distinctive). Frequency of coughing fits was docu-
mented according to patients diary with the scores 0 = no
coughing fits per day, 1 = one coughing fit per day, 2 = 2 –
3 coughing fits per day (i.e. occasionally), 3 = 4–5 cough-
ing fits per day, 4 = 4–9 coughing fits per day (i.e.
frequent), 5 = > 15 coughing fits per day (unbearable
often). Thoracic pain during coughing was measured by
the scores 0 = no, 1 =modest, 2 =moderate, 3 = severe
pain, 4 = unbearable pain. Findings of auscultation were
measured by the scores 0 = no, 1 =modest, 2 =moderate,
3 = relatively distinctive, 4 = distinctive rales. Impairment
of lung function was differentiated by the scores 0 = no,
1 = slight (90 – 99% of predicted value), 2 =moderate
(80 – 90% of predicted value), 3 = strong (70 – 79% of pre-
dicted value) and 4 = very strong impairment (less than
70% of predicted value).
Additionally, symptom-scores were determined for dys-
pnea frequency and intensity during rest, as well as after
exercise (scores: 0 = caused no problems, 1 = occasional
problems, 2 = caused a lot of problems, 3 = the most
important problem the patient had). The frequency of
dyspnea during the course of a week was also gauged and
converted into qualitative scores (scores: 0 = no day was
good, 1 = 1–2 days were good, 2 = 3–4 days were good,
3 = nearly every day was good, 4 = every day was good).
Additionally, coughing and the propensity to cough were
determined, and given by scores (0 = no cough, 1 = in the
morning without complaints, 2 = in the morning with
complaints, 3 = in the morning and over the day (mode-
rate), 3 = in the morning and over the day (severe), 5 =
continuously during whole day (moderate complaints) and
6 = continuously during whole day (relevant complaints).
Visits and randomisation
Randomisation was sequentially assigned in balanced
blocks of 4 from a computer-generated list (random, idv
Data-Analysis& Study Planning, Krailling, Germany).
After the randomisation, the following patient details were
recorded: height; weight; age; time from the first diagnosis
of asthma symptoms; documentation of allergies; con-
comitant disease; prescribed medication; assessment of
the current maintenance therapy. Control visits were
carried out after 4 and 10 days, when adverse events were
recorded and compliance with the treatment plan, as well
as potential changes to therapy were addressed.
Statistical analysis
The proposed sample size for this study was a total of
240 patients for both treatment groups (nnpar (nonpara-
metric), idv, Data-Analysis & Study Planning, Krailling,
Germany). An analysis of efficacy was performed with
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patients, who received at least one dose of medication
and had at least one follow-up visit. The primary out-
come measure was composed by a Bronchitis-Sum-
Score. The statistical analysis of the data was analysed
using the Wilcoxon-Mann–Whitney-U Test, idv, Data-
Analysis & Study Planning, Krailing, Germany). All
secondary outcome measures were analysed using the
Wilcoxon-Mann–Whitney-U Test as well. All data are
expressed as mean values (with SD) and all tests were
two-tailed. P-values of 0.05 or less were considered to
indicate statistical significance.
Results
A total of 242 patients – representing a real-life popu-
lation - were randomised between February 2010 and
January 2011 and received at least one dose of the study
medication. Both treatment groups were well matched
with respect to the baseline characteristics (Table 1).
The mean age of the participants at entry was 41.0 and
43.9 years in the respective groups. The mean duration
of the patients’ acute bronchitis was 3.9 and 4.0 days, re-
spectively. The medication generally was not changed
during the 10 days treatment period. The baseline pa-
rameters in both treatment groups were comparable.
Treatment compliance was determined by counting the
study medication at each visit and was found to be high
and comparable across the treatment groups.
Primary outcome measures
Primary outcome measure was the Bronchitis-Sum-
Score, composed of intensity of dyspnea; quantity of se-
cretion, frequency of coughing fits; thoracic pain during
coughing; rales according to auscultation; and impair-
ment of lung function. After 4 days of treatment theTable 1 Base line characteristics of the patients
Characteristic Placebo Cineole
(N = 121) (N = 121)
Age – yr
Mean (SD) 43.9 (16.5) 41.0 (15.8)
Sex – M/F 54/67 50/71
Weight – kg
Mean (SD) 76.3 (16.5) 77.8 (18.8)
Height – cm
Mean (SD) 172.4 (9.1) 171.7 (9.0)
Days since detection of acute bronchitis
Mean (SD) 4.0 (1.7) 3.9 (1.8)
Bronchitis-Sum-Score
Mean (SD) 9.7 (2.5) 10.0 (2.0)
Smokers/exsmoker 35 32mean decrease was 3.55 score-points in the Cineole
group, and 2.91 score-points in the placebo-group
(Table 2). The difference between both treatment groups
was statistically significant after 4 days (p = 0.0383). Due
to the amelioration of symptoms after seven to ten days
without any medication, the difference between both
treatment groups was found to be distinctive, yet not
statistically significant at the 3rd control-visit after
10 days. At this point, the difference was calculated as
6.82 or 6.52. Comparisons of other single parameters of
the Bronchitis-Sum-Score generally failed to show a sta-
tistically significant difference between both treatment




The statistical significance of the individual parameters
could also be proven, when the influence of treatment
was compared on the basis of the frequency of coughing
fits after 4 days (p = 0.0001). When measuring the cough
documentation against a score generally used in other
fields of research, the predominant parameter “cough”
did not show a characteristic difference between both
treatments (Table 3). Therefore, comparing coughing, or
rather the cough frequency requires the correct de-
finition, in order to show the different progress of
symptoms.
Side effects
A safety examination was carried out on all patients,
who were administered the study medication. Within
the placebo group, it was assumed that two of the recog-
nised and recorded adverse events (e.g. gastrointestinal
infection) were not related to the study medication,
whereas a further AE was interpreted as being related to
an intolerance of the study medication (i.e. heartburn
and burning mouth). During treatment with Cineole 3Table 2 Change of primary outcome measures
Placebo Cineole
Mean of improvementa mean mean P-value*
Of intensity of dyspnea 0.42 (0.75) 0.44 (0.70) 0.8352
Of secretion quantity 0.42 (0.69) 0.44 (0.75) 0.8352
Of cough frequency 0.64 (0.87) 1.18 (1.12) 0.0001
Of thorax pain at coughing 0.58 (0.98) 0.60 (0.98) 0.5896
Of findings at auscultation 0.31 (1.17) 0.35 (1.15) 0.7198
Of lung function 0.42 (0.73) 0.34 (0.70) 0.3249
Of Sum Score 2.91 (2.803) 3.55 (3.022) 0.0383
Composed by the sum of symptoms after 4 days of treatment with cineole
or placebo.
*P-values demonstrate the difference between the two treatment groups.
aDefinition of the scores is defined in the paragraph with the
outcome measures.
Table 3 Comparison of amelioration of cough
Placebo Cineole
Mean Mean P- value*
Frequency of coughing fitsa 0.64 (0.87) 1.18 (1.12) 0.0001
Cough documentationb 1.00 (1.39) 1.30 (1.31) 0.0896
Depending on definition of cough frequency and cough documentation.
Change from baseline until 4 days of treatment with Cineole and placebo.
*P-values demonstrate the difference between the two treatment groups.
aDefinition of the scores is specified for frequency of coughing fits: 0 = no
coughing fits per day, 1 = one coughing fit per day, 2 = 2 – 3 coughing fits per
day (i.e. occasionally), 3 = 4–5 coughing fits per day, 4 = 4–9 coughing fits per
day i.e. frequent) , 5 = > 15 coughing fits per day (unbearable often).
bDefinition of cough documentation is specified by scores: 0 = no cough,
1 = in the morning without complaints, 2 = in the morning with complaints,
3 = in the morning and over the day (moderate), 3 = in the morning and over
the day (severe), 5 = continuously during whole day (moderate complaints)
and 6 = continuously during whole day (relevant complaints) in the paragraph
with the outcome measures.
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study medication (otitis and sinusitis, eye burning, head-
ache). In one case, a patient complained of stomach-
aches, which was interpreted as being related to the
study medication. It has to be noted, that the difference
between the two treatment groups was neither clinically
relevant, nor statistically significant. Safety examinations
of the study and all participating patients highlighted no
notable difference between the two treatment groups.
Discussion
A number of controlled clinical trials on acute bronchitis
have been carried out with view to the investigation of
antibiotics. The results have shown, that antibiotics should
be prescribed with care when other medications fail.
Mucolytic remedies are traditionally used in Europe. A
controlled clinical trial, based on Cineole as the main con-
stituent of eucalyptus oil, had not yet been carried out on
patients with acute bronchitis. In this trial, for the clini-
cally relevant parameter of the reduction of cough fre-
quency a statistically significant effect in favour of Cineole
could be proven, due to the proven anti-inflammatory and
mucolytic effects of this active ingredient.
Acute bronchitis is characterized by coughing that
persists more than 5 days, while about 50% of patients
produce purulent sputum that represents sloughed tra-
cheobronchial epithelium and inflammatory cells. A
rapid diagnostic test identifying a specific pathogen is
normally not recommended. Most cases of acute bron-
chitis are caused by viral infections, where the major
pathogens are influenza A and B viruses, parainfluenza
virus, respiratory syncytial virus, corona virus, adeno-
virus, and rhinovirus. Knowing the pathophysiology it
seems to be evident that antibiotics should not be the
first choice of treatment. Therefore, treatment should
focus on treatment options, which are known to haveboth favourable influence on the pathophysiology, and
that are able to reduce the symptoms of acute bronchitis,
without being limited by a relatively high incidence of side
effects.
Mucociliary dysfunction has direct clinical implications
on the pathophysiological mechanisms of acute bronchitis
[11]. Based on the known anti-inflammatory and broncho-
dilating effects of the natural substance Cineole, it was
assumed that this active ingredient is therapeutically bene-
ficial for patients with acute bronchitis, thus, representing
the necessary parameters of a useful and effective therapy.
An important point is the establishment of the correct
points in time, at which, the parameters of progress of
the symptoms are measured. This has to be viewed in
the context of the duration of the existing diagnosis of
acute bronchitis. This is a major concern in practise, be-
cause only a minority of patients will visit their physician
immediately, following the recognition the first symp-
toms of an acute bronchitis. Therefore, we recruited the
patients on the basis that their symptoms did not last
longer than 7 days. The mean duration since occurrence
of acute bronchitis symptoms was about four days. Thus,
it is not surprising that the difference between the two
groups, following 10 days of treatment with the study
medication, no longer showed to be statistically signifi-
cant. During the treatment period of 4 days the efficacy
of Cineole compared with a placebo could be proven.
The difference between both groups, based upon the
symptom-sum-score and the frequency of coughing fits,
decreased after 10 days, due to the normal course of
symptoms without treatment of the disease. Considering
the mean duration before beginning the treatment of the
symptoms of acute bronchitis will also subside without
treatment with an effective medication. Therefore, show-
ing a statistically significant difference after 4 days of
treatment has to be seen as a further contribution to the
rapid onset of the efficacy of Cineole in treating acute
bronchitis.
The interpretation of the results of this study corrobo-
rates the importance of selecting an effective Sum-Score.
In our study, as in other investigations, we could clearly
show that the number of coughing fits is the most rele-
vant parameter to be chosen as demonstrating the pro-
gress of disease. The other parameters, in the acute
bronchitis Sum-Score, were based on relevant symptoms
of acute bronchitis, without showing equivalent im-
provement in comparison to the frequency of the cough-
ing fits. The explanation for these finding, is that the
baseline for these parameters requires a clear definition
of the in- and exclusion criteria, when planning a study
demonstrating the efficacy by these parameters. But as
coughing is the main and predominant criterion for the
definition of acute bronchitis, other parameters have
only minor influence on the results.
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Cineole is effective in treating acute bronchitis, which
can be explained by its proven pharmacodynamics and
pharmacological properties. In other clinical studies the
anti-inflammatory and also mucolytic effects could be
proven in patients with Rhinosinusitis, COPD and
Asthma. Our findings are complementary with these
former results since the shown anti-tussive effects are
also based on the amelioration of inflammation and of
mucociliary clearance in patients with acute bronchitis.
Our results have to be viewed in the context of the fact
that the disorder affects approximately 5% of adults
annually. It belongs to the 10 most common illnesses
among outpatients. The socio-economic relevance is fur-
ther compounded by the short time frame in which relief
of coughing and coughing fits are achieved, without the
necessity of treatments with antibiotics. Amelioration of
the main symptom frequency of coughing occurs without
significant increase of costs in comparison to other treat-
ment options.
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